Alkermes (ALKS) vs Cytokinetics (CYTK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alkermes (ALKS) has outperformed Cytokinetics (CYTK) over the past year, gaining 33.9% versus a gain of 1.6%. Over five years, CYTK leads with a +65.7% price change compared with +30.9% for ALKS. Cytokinetics is the larger company by market cap ($8.50 billion vs $6.95 billion), about 1.2 times the size.
Alkermes converts more of its revenue into profit, with a net margin of 16.4% versus -891.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALKS | CYTK |
|---|---|---|
| Share price | $41.45 | $61.12 |
| Market cap | $6.95B | $8.50B |
| 1-day change | -0.49% | -0.37% |
| YTD return | +48.12% | -3.81% |
| 1-year return | +33.91% | +1.58% |
| 5-year return | +30.87% | +65.68% |
| P/E ratio (TTM) | 109.07 | — |
| Forward P/E | 22.92 | — |
| EPS (TTM) | $0.38 | $-7.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.48B | $88.04M |
| Revenue growth (YoY) | -5.25% | +376.56% |
| Net income (latest FY) | $241.66M | $-784.96M |
| Gross margin | 86.69% | — |
| Operating margin | 17.21% | -695.44% |
| Net margin | 16.37% | -891.60% |
| 52-week high | $55.67 | $88.31 |
| 52-week low | $27.00 | $54.30 |
| Distance from 52-week high | -25.55% | -30.79% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +36.47% | +79.81% |
| Average volume | 1.83M | 1.95M |
| Shares outstanding | 167.76M | 139.02M |
| Employees | 2,050 | 673 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALKS has outperformed CYTK by 32.3 percentage points over the past year.
- Alkermes is more profitable, keeping 16.4 cents of every revenue dollar as net income versus -891.6 cents for Cytokinetics.
- Cytokinetics grew revenue faster in its latest fiscal year (+376.56% vs -5.25%).
About Alkermes
ALKS stock →Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,050 employees
About Cytokinetics
CYTK stock →Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Health Care · Biotechnology: Pharmaceutical Preparations · 673 employees
ALKS vs CYTK FAQ
Which is bigger, Alkermes or Cytokinetics?
Cytokinetics (CYTK) is larger, with a market capitalization of $8.50B compared with $6.95B for Alkermes (ALKS).
Which stock has performed better over the past year, ALKS or CYTK?
ALKS returned +33.91% over the past 12 months, compared with +1.58% for CYTK (price return, excluding dividends). Past performance does not predict future results.
Are Alkermes and Cytokinetics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.